Johnson & Johnson (ETR:JNJ)
Germany
· Delayed Price · Currency is EUR 154.68
+2.18 (1.43%)
Feb 21, 2025, 5:35 PM CET
Johnson & Johnson Employees
Johnson & Johnson had 138,100 employees as of December 29, 2024. The number of employees increased by 6,200 or 4.70% compared to the previous year.
Employees
138,100
Change (1Y)
6,200
Growth (1Y)
4.70%
Revenue / Employee
€616,730
Profits / Employee
€97,668
Market Cap
373.88B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 138,100 | 6,200 | 4.70% |
| Dec 31, 2023 | 131,900 | -20,800 | -13.62% |
| Jan 1, 2023 | 152,700 | 11,000 | 7.76% |
| Jan 2, 2022 | 141,700 | 7,200 | 5.35% |
| Jan 3, 2021 | 134,500 | 2,300 | 1.74% |
| Dec 29, 2019 | Pro | Pro | Pro |
| Dec 30, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Jan 1, 2017 | Pro | Pro | Pro |
| Jan 3, 2016 | Pro | Pro | Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Siemens Healthineers AG | 72,000 |
| Merck KGaA | 62,908 |
| Bayer Aktiengesellschaft | 96,931 |
| Fresenius SE & Co. KGaA | 193,865 |
| Sartorius Aktiengesellschaft | 13,528 |
| Fresenius Medical Care AG | 119,845 |
| Carl Zeiss Meditec AG | 5,730 |
| Fielmann Group AG | 23,412 |
Johnson & Johnson News
- 3 hours ago - Johnson & Johnson's TREMFYA® Achieves Key Milestones in Ulcerative Colitis Treatment - GuruFocus
- 1 day ago - Final Trade: TEVA, JNJ, TJX, BABA - CNBC
- 1 day ago - JNJ met main goal in late-stage trial for ulcerative colitis treatment - Seeking Alpha
- 1 day ago - TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis - Benzinga
- 1 day ago - TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis - PRNewsWire
- 1 day ago - Teva Pharma and Alvotech launch US biosimilar to J&J's Stelara - Reuters
- 2 days ago - Johnson & Johnson (JNJ) Completes Public Offerings of Notes - GuruFocus
- 3 days ago - AbbVie Vs. Johnson & Johnson: Graham Would Prefer The Consumer Healthcare Giant - Seeking Alpha